Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Post by Haidukon Mar 10, 2015 8:04am

237 Views

Post# 23505293

Germans (PR) still active…

With courtesy of First Berlin Equity Research... while waiting for the news…

I note the sentences: “… the company remains on track with its pipeline of… skin lightening preparations” but that “… royalty payments will begin at the end of 2015”…

I was expecting those royalties to be activated earlier… Nevertheless, target price of CAD 0.90 confirmed (but no timeline mentioned).

Google translate

First Berlin Equity Research has a Sirona Biochem Corp. Research Update (ISIN: CA82967M1005) published. Analyst Ellis Acklin confirmed its BUY recommendation and confirms its target price of CAD 0.90.

Abstract:
Sirona Biochem has published the results for the 2013/14 financial year to 31 October. This was in line with our expectations. The sales amount reached CAD 0.2 million, EBIT was CAD 3.5 million, and the liquidity remained stable. Most importantly, that the company remains on track with its pipeline of anti-diabetic treatment and skin lightening preparations. We expect that royalty payments will begin at the end of 2015 and reiterate our Buy recommendation with a target price of CAD 0.90 based on our pipeline valuation model.

Bullboard Posts

Unique Battery Metals opportunity in Quebec